查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1970812

萘普生市场－全球产业规模、份额、趋势、机会、预测：按应用、销售管道、地区和竞争格局划分，2021-2031年

Naproxen Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By End-Use Application, By Sales Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球萘普生市场预计将从 2025 年的 2.2782 亿美元成长到 2031 年的 3.5061 亿美元，复合年增长率为 7.45%。

萘普生是非类固醇消炎剂(NSAID)，主要用于缓解肌腱炎和关节炎等肌肉骨骼疾病引起的发烧、发炎和疼痛。慢性疼痛疾病在全球范围内的日益普遍以及人口老化的快速发展，都推动了萘普生市场的成长，因为人们对可靠的止痛药的需求日益迫切。此外，萘普生经济实惠，且在非处方药和处方药两种管道均有销售，也进一步促进了其市场成长。根据美国疾病管制与预防中心 (CDC) 预测，到 2024 年，美国约有五分之一的成年人将患有关节炎，这凸显了有效疼痛管理方案的迫切需求。

市场概览
预测期 2027-2031
市场规模：2025年 2.2782亿美元
市场规模：2031年 3.5061亿美元
复合年增长率：2026-2031年 7.45%
成长最快的细分市场 直销
最大的市场 北美洲

然而，儘管市场表现强劲，但长期使用带来的不良健康影响仍构成重大挑战。胃肠道毒性和心血管併发症等严重问题仍然存在，这些风险因素降低了患者的依从性，并限制了药物的长期效用。反过来，这些安全问题也为其他治疗领域挑战萘普生的市场地位创造了机会。

市场驱动因素

慢性发炎性疾病和肌肉骨骼疾病发生率的上升是全球萘普生市场的主要驱动力。萘普生广泛用于治疗僵直性脊椎炎和骨关节炎等疾病，其缓解僵硬和发炎的卓越疗效已得到证实。此外，持续存在的下背痛问题需要长期有效的治疗策略，这也进一步推高了萘普生的需求。根据2025年1月发表在《BMC肌肉骨骼疾病》杂誌上的一篇题为「55岁及以上成年人腰痛的全球、区域和国家负担」的论文，全球约有2.717亿55岁及以上成年人患有腰痛。如此巨大的负担直接推动了处方药和非处方药的稳定销售量，因为患者需要可靠的缓解方法。

同时，由于老年人关节退化风险增加，全球老年人口迅速成长，这是推动市场扩张的关键因素。随着预期寿命的延长，需要接受老龄化相关疾病维持治疗的患者人数不断增加，巩固了萘普生作为重要治疗选择的地位。根据联合国于2024年7月发布的《2024年世界人口展望》报告，全球整体65岁以上人口将达到约8.3亿，构成庞大的病患群体。这一人口趋势也转化为实际的财务表现。例如，拜耳公司于2024年11月发布的《2024年第三季财务业绩报告》显示，其消费者健康部门「疼痛与心血管」类别的销售额增长了10.9%，凸显了市场对镇痛产品的强劲需求。

市场挑战

由于长期使用萘普生存在已知的健康风险，特别是心血管併发症和胃肠道毒性，全球萘普生市场面临许多挑战。这种安全性限制了该药物在慢性肌肉骨骼疾病长期治疗中的应用，并直接阻碍了市场成长。因此，医疗服务提供者变得更加谨慎，限制剂量和疗程以最大程度地减少潜在危害，导致萘普生处方总量下降。此外，患者本身也越来越关注这些严重的副作用，导致用药依从性降低，对非药物疗法和替代止痛药的需求增加。

目前的临床数据进一步证实了风险等级与剂量之间的相关性，从而支持了这种谨慎态度。根据欧洲抗风湿病联盟 (EULAR) 2024 年的报告，与低剂量使用相比，高剂量使用非类固醇抗发炎药物 (NSAIDs) 会使心血管疾病风险增加 10%。这些发现凸显了这些药物存在重大的安全隐患，限制了其商业性潜力，迫使医疗专业人员仔细权衡治疗效益与风险。因此，长期疼痛管理领域的收入成长受到抑制。

市场趋势

市场上，临床治疗通讯协定正明显转向非鸦片类药物合併治疗。医疗专业人员正系统性地以包括萘普生在内的治疗方法取代鸦片类药物单药治疗，以在不产生依赖性风险的情况下控制发炎。指引建议将非类固醇抗发炎药（NSAIDs）列为第一线治疗药物，这直接推动了萘普生在鸦片类药物减量框架中的应用。美国麻醉医师协会（ASA）于2024年12月发布的最新数据也印证了这一趋势，该数据题为《ASA就修订版CDC疼痛管理阿片类药物处方指南的采纳情况提供反馈》。报告显示，约70%的医生已调整其临床实践以符合安全指南，这表明非阿片类替代疗法的使用正在显着增加。

同时，市场正在扩张，透过与网路药局和数位医疗分销管道的整合，患者的用药途径也得到了改善。各大电商平台正利用其物流网络提供处方笺止痛药当日送达服务，满足患者快速缓解疼痛的需求，无需前往实体药局。这种数位化对依赖不间断供应萘普生的行动患者尤其有利。近期公司的发展也印证了这种物流成长的规模。根据亚马逊在2024年10月发布的新闻稿《亚马逊药局将当日配送服务扩展至20个城市》，该公司计划到2025年在另外20个主要都会区推出处方笺药当日配送，预计这将彻底改变人们获取止痛药的方式。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球萘普生市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 最终用途类别（缓解疼痛、抑制发炎、退烧、其他）
    • 销售管道（直销、间接销售）
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美萘普生市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲萘普生市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区萘普生市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：萘普生在中东和非洲的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：萘普生在南美洲的市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球萘普生市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • Jiangxi Tianxin Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Huazhong Pharmaceutical Co., Ltd（HPC）
  • Taj Pharmaceuticals Ltd.
  • Aurobindo Pharma Limited
  • Divi's Laboratories Limited

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 27628

The Global Naproxen Market is projected to expand from USD 227.82 Million in 2025 to USD 350.61 Million by 2031, reflecting a compound annual growth rate of 7.45%. Naproxen, a nonsteroidal anti-inflammatory drug, is predominantly prescribed to mitigate fever, inflammation, and pain linked to musculoskeletal disorders like tendonitis and arthritis. Market expansion is fueled by the escalating global prevalence of chronic pain conditions alongside a rapidly aging population that necessitates reliable analgesic options. This growth is further supported by the medication's economic viability and its broad accessibility in both over-the-counter and prescription forms. According to the Centers for Disease Control and Prevention, in 2024, approximately one in five adults in the United States was affected by arthritis, highlighting the urgent requirement for effective pain management solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 227.82 MIllion
Market Size 2031USD 350.61 MIllion
CAGR 2026-20317.45%
Fastest Growing SegmentDirect Sale
Largest MarketNorth America

However, the market's positive trajectory faces notable hurdles arising from the adverse health effects associated with extended usage. Significant concerns regarding gastrointestinal toxicity and cardiovascular complications continue to pose risks that reduce patient compliance and restrict the drug's long-term utility. These safety issues subsequently create opportunities for competing therapeutic classes to challenge naproxen's market standing.

Market Driver

The rising incidence of chronic inflammatory and musculoskeletal conditions serves as a primary engine for the Global Naproxen Market. The drug is widely adopted for treating ailments such as ankylosing spondylitis and osteoarthritis because of its effectiveness in alleviating stiffness and inflammation. Demand is further intensified by the enduring prevalence of lower back pain, which requires sustained management strategies. According to an article published in BMC Musculoskeletal Disorders in January 2025, titled 'Global, regional, and national burden of low back pain for adults aged 55 and older', roughly 271.7 million people in this demographic experienced low back pain worldwide. This substantial burden directly drives consistent sales volumes for both prescription and over-the-counter formulations as patients search for dependable relief.

Concurrently, the swift growth of the global geriatric population is a significant contributor to market expansion, given that older adults are more prone to joint degeneration. As life expectancies rise, the number of patients needing maintenance therapy for age-related conditions increases, cementing naproxen's status as an essential therapeutic option. According to the United Nations' 'World Population Prospects 2024' report released in July 2024, the global population aged 65 and older has reached approximately 830 million, establishing a massive patient base. This demographic trend translates into concrete financial results; for instance, Bayer reported in its 'Quarterly Statement Third Quarter of 2024' in November 2024 that its Consumer Health division achieved a 10.9% sales increase in the 'Pain & Cardio' category, highlighting the strong demand for analgesic products.

Market Challenge

The Global Naproxen Market confronts substantial obstacles stemming from documented health risks linked to long-term intake, particularly cardiovascular complications and gastrointestinal toxicity. This safety profile directly impedes market growth by limiting the medication's appropriateness for the prolonged management of chronic musculoskeletal disorders. Consequently, healthcare providers are exercising increased caution, frequently restricting dosage or treatment duration to minimize potential harm, which decreases the total volume of naproxen dispensed. Additionally, patient compliance often suffers as individuals become wary of these serious side effects, leading them to seek non-pharmacological interventions or alternative analgesic therapies.

Current clinical data further validates this hesitation by reinforcing the link between risk levels and dosage. According to the European Alliance of Associations for Rheumatology (EULAR) in 2024, the use of high-dose NSAIDs was correlated with a 10% increased risk of cardiovascular disease relative to lower doses. These findings highlight critical safety limitations that restrict the drug's commercial potential, forcing medical professionals to carefully balance therapeutic advantages against these risks, which ultimately suppresses revenue growth within the long-term pain management segment.

Market Trends

The market is increasingly characterized by a clinical shift toward non-opioid multimodal analgesia protocols. Medical professionals are systematically substituting opioid monotherapies with regimens that incorporate naproxen to manage inflammation without the risks of dependence. This transition, encouraged by guidelines promoting NSAIDs as first-line options, directly boosts the adoption of naproxen within opioid-sparing frameworks. Recent data supports this trend; according to the American Society of Anesthesiologists' article 'ASA Provides Feedback on the Uptake of the Revised CDC Guideline for Prescribing Opioids for Pain' published in December 2024, roughly 70% of physicians reported modifying their clinical practices to comply with safety guidelines, highlighting the movement toward non-opioid alternatives.

Simultaneously, the market is broadening its reach through integration with e-pharmacy and digital health distribution channels, which improves patient accessibility. Leading e-commerce platforms are leveraging logistics networks to provide same-day delivery for prescription pain relievers, meeting the demand for prompt relief without the need to visit a physical pharmacy. This digital advancement is especially beneficial for patients with limited mobility who depend on uninterrupted access to naproxen. The magnitude of this logistical growth is illustrated by recent corporate initiatives; according to an Amazon press release in October 2024 titled 'Amazon Pharmacy to Expand Same-Day Delivery to 20 More Cities', the company plans to launch same-day prescription delivery in 20 additional metropolitan areas by 2025, marking a lasting transformation in the acquisition of analgesic medications.

Key Market Players

  • Jiangxi Tianxin Pharmaceutical Co., Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Huazhong Pharmaceutical Co., Ltd (HPC)
  • Taj Pharmaceuticals Ltd.
  • Aurobindo Pharma Limited
  • Divi's Laboratories Limited

Report Scope

In this report, the Global Naproxen Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Naproxen Market, By End-Use Application

  • Pain Relief
  • Inflammation Reduction
  • Fever Reduction
  • Others

Naproxen Market, By Sales Channel

  • Direct Sale
  • Indirect Sale

Naproxen Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Naproxen Market.

Available Customizations:

Global Naproxen Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Naproxen Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By End-Use Application (Pain Relief, Inflammation Reduction, Fever Reduction, Others)
    • 5.2.2. By Sales Channel (Direct Sale, Indirect Sale)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Naproxen Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By End-Use Application
    • 6.2.2. By Sales Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Naproxen Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By End-Use Application
        • 6.3.1.2.2. By Sales Channel
    • 6.3.2. Canada Naproxen Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By End-Use Application
        • 6.3.2.2.2. By Sales Channel
    • 6.3.3. Mexico Naproxen Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By End-Use Application
        • 6.3.3.2.2. By Sales Channel

7. Europe Naproxen Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By End-Use Application
    • 7.2.2. By Sales Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Naproxen Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By End-Use Application
        • 7.3.1.2.2. By Sales Channel
    • 7.3.2. France Naproxen Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By End-Use Application
        • 7.3.2.2.2. By Sales Channel
    • 7.3.3. United Kingdom Naproxen Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By End-Use Application
        • 7.3.3.2.2. By Sales Channel
    • 7.3.4. Italy Naproxen Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By End-Use Application
        • 7.3.4.2.2. By Sales Channel
    • 7.3.5. Spain Naproxen Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By End-Use Application
        • 7.3.5.2.2. By Sales Channel

8. Asia Pacific Naproxen Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By End-Use Application
    • 8.2.2. By Sales Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Naproxen Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By End-Use Application
        • 8.3.1.2.2. By Sales Channel
    • 8.3.2. India Naproxen Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By End-Use Application
        • 8.3.2.2.2. By Sales Channel
    • 8.3.3. Japan Naproxen Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By End-Use Application
        • 8.3.3.2.2. By Sales Channel
    • 8.3.4. South Korea Naproxen Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By End-Use Application
        • 8.3.4.2.2. By Sales Channel
    • 8.3.5. Australia Naproxen Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By End-Use Application
        • 8.3.5.2.2. By Sales Channel

9. Middle East & Africa Naproxen Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By End-Use Application
    • 9.2.2. By Sales Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Naproxen Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By End-Use Application
        • 9.3.1.2.2. By Sales Channel
    • 9.3.2. UAE Naproxen Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By End-Use Application
        • 9.3.2.2.2. By Sales Channel
    • 9.3.3. South Africa Naproxen Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By End-Use Application
        • 9.3.3.2.2. By Sales Channel

10. South America Naproxen Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By End-Use Application
    • 10.2.2. By Sales Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Naproxen Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By End-Use Application
        • 10.3.1.2.2. By Sales Channel
    • 10.3.2. Colombia Naproxen Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By End-Use Application
        • 10.3.2.2.2. By Sales Channel
    • 10.3.3. Argentina Naproxen Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By End-Use Application
        • 10.3.3.2.2. By Sales Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Naproxen Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Jiangxi Tianxin Pharmaceutical Co., Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Teva Pharmaceutical Industries Ltd.
  • 15.3. Huazhong Pharmaceutical Co., Ltd (HPC)
  • 15.4. Taj Pharmaceuticals Ltd.
  • 15.5. Aurobindo Pharma Limited
  • 15.6. Divi's Laboratories Limited

16. Strategic Recommendations

17. About Us & Disclaimer